中国新药杂志

合成卡西酮类物质依赖性评价及相关机制研究进展

PDF下载

张欢 ¹ , 李贝贝 ² , 邱云良 ¹^,²

中国新药杂志 | 综述 2021,30(5): 403-410

收起

中国新药杂志 |综述 2021 , 30 (5) : 403 -410

合成卡西酮类物质依赖性评价及相关机制研究进展

全屏

张欢¹, 李贝贝², 邱云良¹^,²

作者信息

¹上海工程技术大学化学化工学院，上海　201620

²中国医药工业研究总院，上海益诺思生物技术股份有限公司，上海　201203

通讯作者:

邱云良，男，研究员，主要从事新药临床前安全评价研究。联系电话：（021）60211999-3214，E-mail：ylqiu@ncdser.com。

作者简介:

张欢，女，硕士研究生，主要从事新药临床前依赖性评价研究。E-mail：yxz0821@163.com。

Dependency evaluation of synthetic cathinones and related mechanisms

Huan ZHANG¹, Bei-bei LI², Yun-liang QIU¹^,²

Affiliations

¹College of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai 201620, China

²China State Institute of Pharmaceutical Industry, Shanghai InnoStar Bio-Tech Co., Ltd., Shanghai 201203, China

出版时间: 2021-03-15

文章导航

摘要

收起

21世纪初，大量的合成卡西酮流入非法市场，通常以“浴盐”、“植物性食品”的形式在网上售卖，并标有“非供人使用”标签。该物质种类繁多、衍生速度快，其结构或药理学性质与可卡因或甲基苯丙胺类似，经常被滥用，且对个人健康和社会稳定造成极大的影响。为进一步评估合成卡西酮类物质的滥用潜力及其成瘾机制，本文从自主给药实验、药物辨别实验、条件性位置偏爱实验方面对各种动物模型的临床前依赖性评价及相关机制进行综述。

关键词

合成卡西酮 / 卡西酮 / 新精神活性物质 / 依赖性 / 成瘾机制

Abstract

收起

At the beginning of the 21st century, a large number of synthetic cathinones flowed into the illegal market, which are sold as “bath salts” and “plant food” online, and usually labeled “not for human use”. There are a great variety of this kind of substance and they can be rapidly derived. The structures or pharmacological properties of synthetic cathinones are similar to cocaine or methamphetamine, thus they were often abused and had a great impact on personal health and social stability. In order to further evaluate the abuse potential of synthetic cathinones and its mechanism of addiction, the preclinical dependence evaluation and related mechanisms of various animal models are reviewed from the aspects of self-administration, drug discrimination and conditional place preference.

Key words

synthetic cathinones / cathinone / new psychoactive substance / dependence / addiction mechanism

引用本文

张欢, 李贝贝, 邱云良. 合成卡西酮类物质依赖性评价及相关机制研究进展. 中国新药杂志, 2021 , 30 (5) : 403 -410 .

Huan ZHANG, Bei-bei LI, Yun-liang QIU. Dependency evaluation of synthetic cathinones and related mechanisms[J]. Chinese Journal of New Drugs, 2021 , 30 (5) : 403 -410 .

基金

收起

国家“重大新药创制”科技重大专项资助项目(2018ZX 09201017-008)
上海市科委研发公共服务平台资助项目(18DZ2290100)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

[1]

PIEPRZYCA E, SKOWRONEK R, NIŽNANSKÝ Ł, et al. Synthetic cathinones-from natural plant stimulant to new drug of abuse[J]. Eur J Pharmacol, 2020, 875: 173012.

[2]

ZAWILSKA JB, WOJCIESZAK J. Designer cathinones-an emerging class of novel recreational drugs[J]. Forensic Sci Int, 2013, 231(1-3): 42-53.

[3]

GREGG RA, RAWLS SM. Behavioral pharmacology of designer cathinones: a review of the preclinical literature[J]. Life Sci, 2014, 97(1): 27-30.

[4]

EMCDDA E. Europol-EMCDDA Joint Report on a New Psychoactive Substance: 4-Methylmethcathinone (Mephedrone)[EB/OL]. 2010. [2020-11-26]. http://www.emcdda.europa.eu/html.cfm/index132196EN.html

[5]

FASS JA, FASS AD, GARCIA AS. Synthetic cathinones (bath salts): legal status and patterns of abuse[J]. Ann Pharmacother, 2012, 46(3): 436-441.

[6]

BRETTEVILLE-JENSEN AL, TUV SS, BILGREI OR, et al. Synthetic cannabinoids and cathinones: prevalence and markets[J]. Forensic Sci Rev, 2013, 25(1-2): 7-26.

[7]

VALENTE MJ, GUEDES DE PINHO P, DE LOURDES BASTOS M, et al. Khat and synthetic cathinones: a review[J]. Arch Toxicol, 2014, 88(1): 15-45.

[8]

World Health Organization. WHO Expert Committee on Drug Dependence: forty-second report[EB/OL]. (2019) [2020-11-26]. https://apps.who.int/iris/handle/10665/331486.

[9]

NGUYEN JD, GRANT Y, CREEHAN KM, et al. Escalation of intravenous self-administration of methylone and mephedrone under extended access conditions[J]. Addict Biol, 2017, 22(5): 1160-1168.

[10]

VANDEWATER SA, CREEHAN KM, TAFFE MA. Intravenous self-administration of entactogen-class stimulants in male rats[J]. Neuropharmacology, 2015, 99: 538-545.

[11]

CREEHAN KM, VANDEWATER SA, TAFFE MA. Intravenous self-administration of mephedrone, methylone and MDMA in female rats[J]. Neuropharmacology, 2015, 92: 90-97.

[12]

AARDE SM, ANGRISH D, BARLOW DJ, et al. Mephedrone (4-methylmethcathinone) supports intravenous self-administration in Sprague-Dawley and Wistar rats[J]. Addict Biol, 2013, 18(5): 786-799.

[13]

AARDE SM, HUANG PK, CREEHAN KM, et al. The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: self-administration and locomotor activity in rats[J]. Neuropharmacology, 2013, 71: 130-140.

[14]

WATTERSON LR, KUFAHL PR, NEMIROVSKY NE, et al. Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV)[J]. Addict Biol, 2014, 19(2): 165-174.

[15]

SCHINDLER CW, THORNDIKE EB, GOLDBERG SR, et al. Reinforcing and neurochemical effects of the “bath salts” constituents 3,4-methylenedioxypyrovalerone (MDPV) and 3,4-methylenedioxy-N-methylcathinone (methylone) in male rats[J]. Psychopharmacology, 2016, 233(10): 1981-1990.

[16]

AARDE SM, CREEHAN KM, VANDEWATER SA, et al. In vivo potency and efficacy of the novel cathinone α-pyrrolidinopentiophenone and 3,4-methylenedioxypyrovalerone: self-administration and locomotor stimulation in male rats[J]. Psychopharmacology, 2015, 232(16): 3045-3055.

[17]

CHEONG JH, CHOI MJ, JANG CG, et al. Behavioral evidence for the abuse potential of the novel synthetic cathinone alpha-pyrrolidinopentiothiophenone (PVT) in rodents[J]. Psychopharmacology (Berl), 2017, 234(5): 857-867.

[18]

COLLINS GT, SULIMA A, RICE KC, et al. Self-administration of the synthetic cathinones 3,4-methylenedioxypyrovalerone (MDPV) and α-pyrrolidinopentiophenone (α-PVP) in rhesus monkeys[J]. Psychopharmacology (Berl), 2019, 236(12): 3677-3685.

[19]

GLENNON RA, YOUNG R. Neurobiology of 3,4-methylenedioxypyrovalerone (MDPV) and α-pyrrolidinovalerophenone (α-PVP)[J]. Brain Res Bull, 2016, 126(Pt 1): 111-126.

[20]

BARRIO P, GASKELL M, GOTI J, et al. Síntomas psicóticos persistentes después del uso abusivo prolongado de mefedrona: Una serie de dos casos[J]. Adicciones, 2016, 28(3): 154.

[21]

SEWALIA K, WATTERSON LR, HRYCIW A, et al. Neurocognitive dysfunction following repeated binge-like self-administration of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV)[J]. Neuropharmacology, 2018, 134(Pt A): 36-45.

[22]

BOTANAS CJ, YOON SS, DE LA PEÑA JB, et al. The abuse potential of two novel synthetic cathinones with modification on the alpha-carbon position, 2-cyclohexyl-2-(methylamino)-1-phenylethanone (MACHP) and 2-(methylamino)-1-phenyloctan-1-one (MAOP), and their effects on dopaminergic activity[J]. Pharmacol Biochem Behav, 2017, 153: 160-167.

[23]

HWANG JY, KIM JS, OH JH, et al. The new stimulant designer compound pentedrone exhibits rewarding properties and affects dopaminergic activity[J]. Addict Biol, 2017, 22(1): 117-128.

[24]

BOTANAS CJ, YOON SS, DE LA PEÑA JB, et al. A novel synthetic cathinone, 2-(methylamino)-1-(naphthalen-2-yl) propan-1-one (BMAPN), produced rewarding effects and altered striatal dopamine-related gene expression in mice[J]. Behav Brain Res, 2017, 317: 494-501.

[25]

BOTANAS CJ, YOON SS, DE LA PEÑA JB, et al. The abuse potential of α-piperidinopropiophenone (PIPP) and α-piperidinopentiothiophenone (PIVT), two new synthetic cathinones with piperidine ring substituent[J]. Biomol Ther (Seoul), 2017, 25(2): 122-129.

[26]

FDA. Guidance for industry: assessment of abuse potential of drugs[EB/OL]. (2017) [2020-11-26]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessment-abuse-potential-drugs.

[27]

GATCH MB, TAYLOR CM, FORSTER MJ. Locomotor stimulant and discriminative stimulus effects of “bath salt” cathinones[J]. Behav Pharmacol, 2013, 24(5-6): 437-447.

[28]

GATCH MB, RUTLEDGE MA, FORSTER MJ. Discriminative and locomotor effects of five synthetic cathinones in rats and mice[J]. Psychopharmacology (Berl), 2015, 232(7): 1197-1205.

[29]

GATCH MB, TAYLOR CM, FORSTER MJ. Locomotor activity and discriminative stimulus effects of five novel synthetic cathinone analogs in mice and rats[J]. Psychopharmacology, 2017, 234(8): 1237-1245.

[30]

GATCH MB, DOLAN SB, FORSTER MJ. Methylenedioxymethamphetamine-like discriminative stimulus effects of seven cathinones in rats[J]. Behav Pharmacol, 2020, 31(4): 378-384.

[31]

GATCH MB, DOLAN SB, FORSTER MJ. Locomotor activity and discriminative stimulus effects of five novel synthetic cathinone analogs in mice and rats[J]. Drug Alcohol Depend, 2019, 199: 50-58.

[32]

NAYLOR JE, FREEMAN KB, BLOUGH BE, et al. Discriminative-stimulus effects of second generation synthetic cathinones in methamphetamine-trained rats[J]. Drug Alcohol Depend, 2015, 149: 280-284.

[33]

SMITH DA, BLOUGH BE, BANKS ML. Cocaine-like discriminative stimulus effects of amphetamine, cathinone, methamphetamine, and their 3,4-methylenedioxy analogs in male rhesus monkeys[J]. Psychopharmacology (Berl), 2017, 234(1): 117-127.

[34]

SMITH DA, NEGUS SS, POKLIS JL, et al. Cocaine-like discriminative stimulus effects of alpha-pyrrolidinovalerophenone, methcathinone and their 3,4-methylenedioxy or 4-methyl analogs in rhesus monkeys[J]. Addict Biol, 2017, 22(5): 1169-1178.

[35]

COLLINS GT, ABBOTT M, GALINDO K, et al. Discriminative stimulus effects of binary drug mixtures: studies with cocaine, MDPV, and caffeine[J]. J Pharmacol Exp Ther, 2016, 359(1): 1-10.

[36]

RILEY AL, NELSON KH, TO P, et al. Abuse potential and toxicity of the synthetic cathinones (i.e., “Bath salts”)[J]. Neurosci Biobehav Rev, 2020, 110: 150-173.

[37]

LISEK R, XU W, YUVASHEVA E, et al. Mephedrone (‘bath salt’) elicits conditioned place preference and dopamine-sensitive motor activation[J]. Drug Alcohol Depend, 2012, 126(1-2): 257-262.

[38]

GREGG RA, BAUMANN MH, PARTILLA JS, et al. Stereochemistry of mephedrone neuropharmacology: enantiomer-specific behavioural and neurochemical effects in rats[J]. Br J Pharmacol, 2015, 172(3): 883-894.

[39]

GANNON BM, RUSSELL LN, MODI MS, et al. Effects of orally self-administered bath salt constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice[J]. Drug Alcohol Depend, 2017, 179: 408-415.

[40]

KARLSSON L, ANDERSSON M, KRONSTRAND R, et al. Mephedrone, methylone and 3,4-methylenedioxypyrovalerone (MDPV) induce conditioned place preference in mice[J]. Basic Clin Pharmacol Toxicol, 2014, 115(5): 411-416.

[41]

GATCH MB, DOLAN SB, FORSTER MJ. Comparative behavioral pharmacology of three pyrrolidine-containing synthetic cathinone derivatives[J]. J Pharmacol Exp Ther, 2015, 354(2): 103-110.

[42]

ANGOA-PÉREZ M, ANNEKEN JH, KUHN DM. Neurotoxicology of synthetic cathinone analogs[J]. Curr Top Behav Neurosci, 2017, 32: 209-230.

[43]

REITH MEA, BLOUGH BE, HONG WC, et al. Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter[J]. Drug Alcohol Dependence, 2015, 147: 1-19.

[44]

HONDEBRINK L, ZWARTSEN A, WESTERINK RHS. Effect fingerprinting of new psychoactive substances (NPS): What can we learn from in vitro data?[J]. Pharmacol Ther, 2018, 182: 193-224.

[45]

LUETHI D, WALTER M, ZHOU X, et al. Para-halogenation affects monoamine transporter inhibition properties and hepatocellular toxicity of amphetamines and methcathinones[J]. Front Pharmacol, 2019, 10: 438.

[46]

RICKLI A, HOENER MC, LIECHTI ME. Monoamine transporter and receptor interaction profiles of novel psychoactive substances: Para-halogenated amphetamines and pyrovalerone cathinones[J]. Eur Neuropsychopharmacol, 2015, 25(3): 365-376.

[47]

FORTIN SM, ROITMAN MF. Challenges to body fluid homeostasis differentially recruit phasic dopamine signaling in a taste-selective manner[J]. J Neurosci, 2018, 38(31): 6841-6853.

[48]

BERNSTEIN DL, NAYAK SU, OLIVER CF, et al. Methylenedioxypyrovalerone (MDPV) impairs working memory and alters patterns of dopamine signaling in mesocorticolimbic substrates[J]. Neurosci Res, 2020, 155: 56-62.

[49]

STEFANI MR, MOGHADDAM B. Rule learning and reward contingency are associated with dissociable patterns of dopamine activation in the rat prefrontal cortex, nucleus accumbens, and dorsal striatum[J]. J Neurosci, 2006, 26(34): 8810-8818.

[50]

GYGI MP, GIBB JW, HANSON GR. Methcathinone: an initial study of its effects on monoaminergic systems[J]. J Pharmacol Exp Ther, 1996, 276(3): 1066-1072.

[51]

MARTÍNEZ-CLEMENTE J, ESCUBEDO E, PUBILL D, et al. Interaction of mephedrone with dopamine and serotonin targets in rats[J]. Eur Neuropsychopharmacol, 2012, 22(3): 231-236.

[52]

BAUMANN MH, AYESTAS MA, PARTILLA JS, et al. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue[J]. Neuropsychopharmacology, 2012, 37(5): 1192-1203.

[53]

GUDELSKY GA, YAMAMOTO BK, NASH JF. Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists[J]. Eur J Pharmacol, 1994, 264(3): 325-330.

[54]

MARTÍNEZ-CLEMENTE J, LÓPEZ-ARNAU R, ABAD S, et al. Dose and time-dependent selective neurotoxicity induced by mephedrone in mice[J]. PLoS One, 2014, 9(6): e99002.

[55]

LÓPEZ-ARNAU R, MARTÍNEZ-CLEMENTE J, RODRIGO T, et al. Neuronal changes and oxidative stress in adolescent rats after repeated exposure to mephedrone[J]. Toxicol Appl Pharmacol, 2015, 286(1): 27-35.

[56]

COZZI NV, SIEVERT MK, SHULGIN AT, et al. Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines[J]. Eur J Pharmacol, 1999, 381(1): 63-69.

[57]

PEREIRA VS, HIROAKI-SATO VA. A brief history of antidepressant drug development: from tricyclics to beyond ketamine[J]. Acta Neuropsychiatr, 2018, 30(6): 307-322.

[58]

NESTLER EJ. Molecular basis of long-term plasticity underlying addiction[J]. Nat Rev Neurosci, 2001, 2(2): 119-128.

2021年第30卷第5期

PDF下载

引用本文

BibTeX

文章信息

首发时间：2026-10-29
出版时间：2021-03-15

补充材料

相关文章

文章信息

作者

出版历史

录用日期：2020-10-22

基金

国家“重大新药创制”科技重大专项资助项目(2018ZX 09201017-008)

上海市科委研发公共服务平台资助项目(18DZ2290100)

作者信息

¹上海工程技术大学化学化工学院，上海　201620

²中国医药工业研究总院，上海益诺思生物技术股份有限公司，上海　201203

通讯作者:

邱云良，男，研究员，主要从事新药临床前安全评价研究。联系电话：（021）60211999-3214，E-mail：ylqiu@ncdser.com。

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zgxyzz/CN/1322627797349155067

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT